PROCARE - PROstate Cancer Real World Evidence Registry

Launched by UROTRIALS COMPANY (GMBH) · Feb 13, 2025

Keywords

ClinConnect Summary

The PROCARE study is a clinical trial aimed at understanding the treatment and progression of prostate cancer in patients with different stages of the disease. Specifically, it focuses on men who have experienced a rise in their PSA levels after previous treatments, such as surgery or radiation. This includes those with prostate cancer that has returned but hasn’t spread, those whose cancer has spread but is still responding to hormone therapy, and those whose cancer continues to progress despite hormone treatment. By gathering information from these various patient groups, researchers hope to better understand how to manage and treat prostate cancer over the long term.

To participate in this study, patients must be at least 18 years old and have been diagnosed with one of the specific types of prostate cancer mentioned. They should also be starting a new treatment for their cancer or have done so within the last four weeks. Participants will be monitored regularly to track their treatment and health outcomes. This study is currently recruiting, so if you or a loved one are eligible, you may have the opportunity to contribute to important research that could benefit future prostate cancer patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Adult prostate cancer patients (age ≥18 years).
• • Diagnosis at time of study inclusion Cohort 1: biochemical recurrence (BCR) after local curative intended treatment (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof) Cohort 2: non-metastatic castration-resistant prostate cancer (nmCRPC) or Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or Cohort 4: metastatic castration-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line)
• • Patients who will receive a new line of systemic therapy at the time of study entry or up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a new diagnosis of mCRPC (=first line mCRPC) after either treatment for mHSPC or non-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, ... line).
• • For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging) to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) or local treatment is declined by the patient.
• • Patients, who are able and willing to sign the informed consent form
• Exclusion Criteria:
• • • Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician